INTRODUCTION
HISTORY
PRINCIPLES OF WORKING OF A LASER
FUNDAMENTALS OF LASER
CHARACTERISTICS OF LASER
CLASSIFICATION OF LASER
EFFECTS OF LASER ON SOFT AND HARD TISSUES
VARIOUS LASERS AVAILABLE FOR PERIDONTAL USE
APPLICATION OF LASER TREATMENT IN PERIODONTAL THERAPY
ADVANTAGES & DISADVANTAGES OF LASER IN PERIODONTAL THERAPY
LASER PRECAUTIONS
LASER HAZARDS
RECENT ADVANCES
CONCLUSION
REFERENCES TAKEN FROM CARRANZA'S TEXTBOOK OF CLINICAL PERIODONTOLOGY AND LINDHE'S TEXTBOOK OF CLINICAL PERIODONTOLOGY AND IMPLANT DENTISTRY. CONTAINS ENOUGH AND MORE DETAILS OF THIS TOPIC FOR BDS STUDENTS.HOPE THIS PRESENTATION WILL HELP U GAIN SOME KNOWLEDGE ABOUT PERIODONTAL PLASTIC AND ESTHETIC DENTISTRY.
INTRODUCTION
HISTORY
PRINCIPLES OF WORKING OF A LASER
FUNDAMENTALS OF LASER
CHARACTERISTICS OF LASER
CLASSIFICATION OF LASER
EFFECTS OF LASER ON SOFT AND HARD TISSUES
VARIOUS LASERS AVAILABLE FOR PERIDONTAL USE
APPLICATION OF LASER TREATMENT IN PERIODONTAL THERAPY
ADVANTAGES & DISADVANTAGES OF LASER IN PERIODONTAL THERAPY
LASER PRECAUTIONS
LASER HAZARDS
RECENT ADVANCES
CONCLUSION
REFERENCES TAKEN FROM CARRANZA'S TEXTBOOK OF CLINICAL PERIODONTOLOGY AND LINDHE'S TEXTBOOK OF CLINICAL PERIODONTOLOGY AND IMPLANT DENTISTRY. CONTAINS ENOUGH AND MORE DETAILS OF THIS TOPIC FOR BDS STUDENTS.HOPE THIS PRESENTATION WILL HELP U GAIN SOME KNOWLEDGE ABOUT PERIODONTAL PLASTIC AND ESTHETIC DENTISTRY.
A brief description of all topics to recent advances,SDD, host modulation and diabetes, host modulation in smokers, chemically modified tetracyclines, bisphosphonates
INTRODUCTION
DEFINITION
TYPES OF TRAUMA FROM OCCLUSION
GLICKMAN CONCEPT
WAERHAUG CONCEPT
STAGES OF TISSUE RESPONSE TO INJURY
CLINICAL AND RADIOGRAPHIC FEATURES OF TFO
CLINICAL DIAGNOSIS OF TFO
TFO AND IMPLANTS
TREATMENT OF TFO
CONCLUSION
REFRENCES
Occlusion, in a dental context, means simply the contact between teeth. More technically, it is the relationship between the maxillary (upper) and mandibular (lower) teeth when they approach each other, as occurs during chewing or at rest.
Malocclusion is the misalignment of teeth and jaws, or more simply, a "bad bite". Malocclusion can cause a number of health and dental problems.
Static occlusion refers to contact between teeth when the jaw is closed and stationary, while dynamic occlusion refers to occlusal contacts made when the jaw is moving. Dynamic occlusion is also termed as articulation. During chewing, there is no tooth contact between the teeth on the chewing side of the mouth.
Centric occlusion is the occlusion of opposing teeth when the mandible is in centric relation. Centric occlusion is the first tooth contact and may or may not coincide with maximum intercuspation. It is also referred to as a person's habitual bite, bite of convenience, or intercuspation position (ICP). Centric relation, not to be confused with centric occlusion, is a relationship between the maxilla and mandible. Dr Harshavardhan Patwal , Malocclusion is the result of the body trying to optimize its function in a dysfunctional environment. It can be associated with a number of problems, including crooked teeth, gum problems, the temporomandibular joint (TMJ), and jaw muscles. Teeth, fillings, and crowns may wear, break, or loosen, and teeth may be tender or ache. Receding gums can be exacerbated by a faulty bite. If the jaw is mispositioned, jaw muscles may have to work harder, which can lead to fatigue and or muscle spasms. This in turn can lead to headaches or migraines, eye or sinus pain, and pain in the neck, shoulder, or even back. Malocclusion can be a contributing factor to sleep disordered breathing which may include snoring, upper airway resistance syndrome, and / or sleep apnea (apnea means without breath). Untreated damaging malocclusion can lead to occlusal trauma.
Some of the treatments for different occlusal problems include protecting the teeth with dental splints (orthotics), tooth adjustments, replacement of teeth, medication (usually temporary), a diet of softer foods, TENS to relax tensed muscles, and relaxation therapy for stress-related clenching. Removable dental appliances may be used to alter the development of the jaws. Fixed appliances such as braces may be used to move the teeth in the jaws. Jaw surgery is also used to correct malocclusion.
Certains medications have been associated with gingival enlargement.
the seminar gives a complete analysis of etilogy and pathogenesis involved in digo as well as sequlae of it
A brief description of all topics to recent advances,SDD, host modulation and diabetes, host modulation in smokers, chemically modified tetracyclines, bisphosphonates
INTRODUCTION
DEFINITION
TYPES OF TRAUMA FROM OCCLUSION
GLICKMAN CONCEPT
WAERHAUG CONCEPT
STAGES OF TISSUE RESPONSE TO INJURY
CLINICAL AND RADIOGRAPHIC FEATURES OF TFO
CLINICAL DIAGNOSIS OF TFO
TFO AND IMPLANTS
TREATMENT OF TFO
CONCLUSION
REFRENCES
Occlusion, in a dental context, means simply the contact between teeth. More technically, it is the relationship between the maxillary (upper) and mandibular (lower) teeth when they approach each other, as occurs during chewing or at rest.
Malocclusion is the misalignment of teeth and jaws, or more simply, a "bad bite". Malocclusion can cause a number of health and dental problems.
Static occlusion refers to contact between teeth when the jaw is closed and stationary, while dynamic occlusion refers to occlusal contacts made when the jaw is moving. Dynamic occlusion is also termed as articulation. During chewing, there is no tooth contact between the teeth on the chewing side of the mouth.
Centric occlusion is the occlusion of opposing teeth when the mandible is in centric relation. Centric occlusion is the first tooth contact and may or may not coincide with maximum intercuspation. It is also referred to as a person's habitual bite, bite of convenience, or intercuspation position (ICP). Centric relation, not to be confused with centric occlusion, is a relationship between the maxilla and mandible. Dr Harshavardhan Patwal , Malocclusion is the result of the body trying to optimize its function in a dysfunctional environment. It can be associated with a number of problems, including crooked teeth, gum problems, the temporomandibular joint (TMJ), and jaw muscles. Teeth, fillings, and crowns may wear, break, or loosen, and teeth may be tender or ache. Receding gums can be exacerbated by a faulty bite. If the jaw is mispositioned, jaw muscles may have to work harder, which can lead to fatigue and or muscle spasms. This in turn can lead to headaches or migraines, eye or sinus pain, and pain in the neck, shoulder, or even back. Malocclusion can be a contributing factor to sleep disordered breathing which may include snoring, upper airway resistance syndrome, and / or sleep apnea (apnea means without breath). Untreated damaging malocclusion can lead to occlusal trauma.
Some of the treatments for different occlusal problems include protecting the teeth with dental splints (orthotics), tooth adjustments, replacement of teeth, medication (usually temporary), a diet of softer foods, TENS to relax tensed muscles, and relaxation therapy for stress-related clenching. Removable dental appliances may be used to alter the development of the jaws. Fixed appliances such as braces may be used to move the teeth in the jaws. Jaw surgery is also used to correct malocclusion.
Certains medications have been associated with gingival enlargement.
the seminar gives a complete analysis of etilogy and pathogenesis involved in digo as well as sequlae of it
Development of bone
Microstructure of bone
Composition of bone
Formation of osteoblasts
Mineralisation of bone
Formation of osteoclasts
Resorption of bone
Macrostructure of bone
Volume changes in bone
Bone healing
alveolar bone in health with microscopic features and details about bone formation, resorption also includes bone remodelling and changes after extraction
The Pathophysiology of Obesity and its medical management in detail with future strategies for Prohibitin binding and the destruction of the blood supply to Adipose Tissue
Engineering Assisted Surgery - Robots and NanobotsNinian Peckitt
Engineering Assisted Surgery is the application of Industrial Manufacturing Technology to the delivery of Healthcare. Professor Peckitt discusses the application of Robots and Nanobots in this presentation
The Origins and Failure of Health Reforms are presented in cartoon format with an analysis of System Failure in the NHS and dysfunctional management. The solutions are obvious.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
4. RANKL Knockout Mice
• severe osteopetrosis / defects in tooth eruption (25)
• complete absence of osteoclasts
• defects of T and B cells / lack lymph nodes
– defects in thymic differentiation
– normal splenic structure and Peyer’s patches (25)
• Unexpected defects in mammary gland development (26)
5. Osteoclastogenesis
Basic Multicellular Units.
Bone constantly resorbed and formed at specific sites
1. Osteoclast Migration to sites (activation)
2. resorption of a packet of bone
3. a reversal phase characterized by:
– apoptosis of the osteoclasts
– followed by a phase of bone formation by newly formed osteoblasts
11. Drug and Bone
• Antiresorptive (also called anti-catabolic)
– Estrogens
– bisphosphonates (eg, alendronate, risedronate, ibandronate, zoledronate),
– Calcitonin
– raloxifene
• Anabolic (Riggs and Parfitt 2005)
Teriparatide, recombinant human (PTH) 1–34,
anabolic / bone forming - strengthens bone and reduces fracture risk
increasing bone formation / size
• Antiresorbtive and Anabolic
Strontium ranelate,
Dual action antiresorptive and anabolic properties.
• Stabilisationor increase BMD:
– filling in the remodeling space and prolonging secondary mineralization
– maintaining bone microarchitecture
– reducing trabecular perforation,
– ecreasing cortical porosity.
12. Bisphosphonates - Basic Chemistry
• Pyrophosphate
• Substitution of Carbon for Oxygen
– Resistance to hydrolysis
– Bone matrix accumulation
– Extremely long half-life
• Nitrogen-containing side chain
– Increases potency, toxicity
– Direct link to ONJ cases
13. Action of Bisphosphonates
• Osteoclastic toxicity
– Apoptosis
– Inhibited release of bone induction proteins
BMP, ILG1, ILG2
– Reduced bone turnover, resorption
– Reduced serum calcium
– Hypermineralisation
“sclerotic” changes lamina dura - alveolar bone
14. Medical Indications for IV BPs
• Bone metastasis
• Hypercalcemia
• RANKL-mediated osteoclastic resorption
• Multiple myeloma,
• Breast CA, Prostate CA
• Paracrine-like effect
• PTH-like peptide osteoclastic resorption
• Small cell carcinoma
• oropharyngeal cancers
• Endocrine-like effect
15. Indications for Oral Bisphosphonates
• Paget’s Disease of bone
– Accelerated bone turnover
– Reduced compressive strength
– increased vascularity
– Bone pain
– Elevated AP levels
• Osteoporosis
Effects of estrogen loss:
– Decreased bone turnover / renewal
– Adipocyte differentiation
– osteoblastic differentiation
– increased fibrofatty marrow
– Progressively porotic bone
– DEXA scan for BMD values
Paget’s Disease
16. Pharmacokinetics
• Oral Bisphosphonates
– Absorbed in small intestine
– Less if taken with meal
– 1-10% available to bone
• Circulating half-life: 0.5-2 hrs
– Rapid uptake into bone matrix
– 30-70% of IV/oral dose accumulates in bone
– Remainder excreted in urine
• Repeated doses accumulate in bone
– Removed only by osteoclast-mediated resorption
– “Biologic Catch 22”
17. Denosumab
• More potent inhibitor of osteoclasts
• Binds to RANKL cf osteoprotegerin (OPG) – Longer Duration
• prevents interaction of RANKL and RANK
• reduces osteoclast
– Differentiation
– Activity
– survival
• inhibits bone resorption
19. Denosumab
• Osteonecrosis of the Jaws (ONJ) Reported
• ONJ - Function of Osteoclast Depletion
• Common Problem with all drugs inhibiting Osteoclasis
• Denosumab ONJ reversible ?
• Note CTX levels may be very low <10pg/ml
• Rate of recovery faster than Bisphosphonates?
• CTX Monitoring required
20. Osteonecrosis of the Jaws
Definition ONJ (Sawatari and Marx 2007)
Exposed bone in the mandible or maxilla
that fails to heal within 8 weeks in a patient
receiving, or who has received, a systemic
bisphosphonate, and who has not received
local radiation therapy to the jaws.
ONJ
• following oral surgery (dental extraction)
• spontaneous cases are recorded
• Alveolar Bone x15 turnover (Marx)
21. Classification of Osteonecrosis of the Jaws
Grade Severity
1 Asymptomatic
2 Mild
3 Moderate
4 Severe
Grade Size (diameter*)
1A Single lesion, <0.5 cm
1B
Multiple lesions, largest <0.5
cm
2A Single lesion <1.0 cm
2B
Multiple lesions, largest <1.0
cm
3A Single lesion, ≤2.0 cm
3B
Multiple lesions, largest ≤2.0
cm
4A Single lesion >2.0 cm
4B
Multiple lesions, largest >2.0
cm
*Lesion size measured as the largest diameter
22. AAOMS Staging of ONJ
• Patients at risk (Subclinical)
• No apparent exposed/necrotic bone in pts treated w/ IV or oral BPs
• Patients with ONJ
• Stage 1: Exposed/necrotic bone, asymptomatic, no infection
• Stage 2: Exposed/necrotic bone, pain, infection
• Stage 3: Exposed/necrotic bone, pain, infection + :
Pathologic fracture
or … extra-oral fistula
Or … osteolysis extending to inferior border
26. AAOMS Stage 0 Lesions
• Spontaneous Numbness and Pain
• No exposed bone
• No prior dental antecedent
• Positive image findings:
– Sclerosis
– Positive bone scan
27. Osteonecrosis of the Jaws
ONJ (Sawatari and Marx 2007)
• 6 doses of monthly iv biphosphonate or
• 3 yrs of weekly alendronate or risedronate
are required…….
…….. before a patient is at risk for ONJ
96% ONJ - iv bisphosphonates
4% ONJ - oral bisphosphonates
Note 25-35% non compliance for Oral Medication
28. Osteonecrosis of the Jaws
ONJ http://jada.ada.org/cgi/content/full/137/8/1144
• Initially denied by Industry – (Dr R.E. Marx attacked when ONJ reported)
• ONJ Low Risk 0.7 per 100,000 person-years’exposure to alendronate (Fosamax)
• but reported 25-35% non compliance in oral medication
• 50% compliance required for therapeutic effect www.ncbi.nlm.nih.gov/pmc/articles/PMC3017316/
• Risk is therefore underestimated by circa 35%
• Other nitrogen-containing oral bisphosphonates expected to have a similar risk profile
• ONJ can occur spontaneously
• ONJ associated with dental extractions
• ONJ increase >65 years
29. Risk of ONJ www.ncbi.nlm.nih.gov/pmc/articles/PMC3017316/
Risk is under-reported (Peckitt)
• 25-35% of patients non compliant on Oral Therapy
• 50% compliancy required for therapeutic effect (Oral Drugs)
• There is a move towards i.v. drugs to improve compliance
• Move to i.v. drugs will increase the risk of ONJ significantly
• Advanced ONJ is probably untreatable and causes significant morbidity
Osteonecrosis of the Jaws
30. Risk of ONJ www.ncbi.nlm.nih.gov/pmc/articles/PMC3017316/
The consequences of a severe complication and its treatability
• require computation into Risk/Benefit Analysis
• before safety guidelines are formulated
• A “rare” serious complication is not necessarily acceptable
– if the effect of bisphosphonates is irreversible
– if there is no effective treatment for advanced stages of ONJ
– Patient Safety takes Priority over Financial Profit
In a multibillion $ Industry - Marketing ≠ Science
Osteonecrosis of the Jaws
31. Osteonecrosis of the Jaws
ONJ http://jada.ada.org/cgi/content/full/137/8/1144
• ONJ Oral gluco-corticoid use for chronic conditions
• ONJ – associated with Periodontitis
• ONJ associated with prolonged use of bisphosphonates
• ONJ bilateral and multifocal reports in cancer patients
• ONJ Tori and other bony exostoses may increase the risk of developing ONJ.
32. Tori
Torus Maxillaris and Mandibularis
• Midline Palate
• Lingual side of premolars (90 % Bilateral )
• Familial Incidence 5-40%
• Occur early in Life / Associated with Bruxism
• Size of Torus correlates with increased bone Density
- Post Menopausal women
http://jcem.endojournals.org/cgi/content/full/88/5/2081
34. Bis-Phossyjaw?
• Phossy jaw - white phosphorus 19th Cent
• Phosphonecrosis of the Jaw
– Unusual necrosis of the Jaw in (Young) Match Workers
– Pain and Disfigurement
– Eerie glow in the dark (phosphorescence)
• Tip of the Iceberg – Potential Epidemic?
35. Estimation of Bone Turnover
The C-terminal telopeptide (CTX) blood test (β Cross Laps)
• Fasting Saerum CTX Test - an index of bone turnover
• Cross linked octapeptide fragment from type 1 bone collagen is released (98% of bone protein)
– released when osteoclasts resorb bone
– Serum CTX level α osteoclastic resorbiton at time blood is drawn
– CTX 50 pg/mL - 450pg/mL 1
– Normal values > 300pg/mL and commonly 400-550pg/mL 1
• Risk assessment,2 suggests a value of
– <100 pg/mL is high risk
– >150 pg/mL is low risk
– Australian trial 3 favours >200 pg/mL as a safe level for a bone invasive procedure.
1. Marx RE : J Oral Maxillofac Surg 65:2397-2410, 2007
2. Therapeutic Guidelines. Therapeutic guidelines: oral and
dental. Melbourne: TG, 2007
3. Goss AN. CTX (the cross laps test). Australian Dental
Association Bulletin 2008; 368:11
36. CTX and ONJ Prevention
Kunchur, Need, Hughes Goss (Adelaide)
• 348 Patients Fasted Morning Test
• 222 Patients at Risk
• 15 Patients had ONJ
• 113 Controls
Kunchur R, Need A, Hughes T Goss A
Clinical Investigation of C-Terminal Cross Linking Telopeptide Test in
Prevention and Management of Bisphosphonate-ssociated Osteonecrosis of
the Jaws
JOMS 2009: 7, 1167-1173
37. Kunchur, Need, Hughes Goss (Adelaide)
Long term Bisphosphonates n=215
• Older Med Compromised Patients (71 ± 11.6 yrs)
• Average CTX 238 ± 144 pg/ml
• 98pts <200pg/ml
1pt CTX = 126pg/ml ONJ
38. Kunchur, Need, Hughes Goss (Adelaide)
IV Bisphosphonates
7 pts NO ONJ CTX= 329 ± 354 (with 4 < 200pg/ml)
15pt ONJ
12pts post extraction
3pts spontaneously
7 pts no drug holiday CTX = 116 pg/ml
39. Kunchur, Need, Hughes Goss (Adelaide)
CTX < 150pg/ml
Did not correlate with clinical risk factors of....
Age
Gender
Co-morbidities
Bone Disease
Bisphosphonate Duration
40. Kunchur, Need, Hughes Goss (Adelaide)
Statistical Differnece - Aledronate compared with risedronate (p< .0001)
Bisphosphonates: Anti-Resorptive potency
Drug Trade Name Potency Adminitration
etidronate Osteum Difosen 1 Orally
clodronate Bonefos 10 Orally / iv
tiludronate Skelid 10 Orally
pamidronate Aredia, Linoten, Pamifos, Xinsidona 100 iv
alendronate Fosamax Fosavance 1,000 Orally
risedronate Actonel Acrel 5,000 Orally
ibandronate Bondronat 10,000 Orally / iv
zoledronate Zometa Aclasta 85,000 iv
41. Kunchur, Need, Hughes Goss (Adelaide)
Drug Holiday
CTX Value circa 25pg/ml/month
42. Kunchur, Need, Hughes, Goss (Adelaide)
Conclusions
• CTX not presictive of ONJ (individual patient)
• Risk Zone 150-200pg/ml
• If medically appropriate cease bisphosphonate
• Until patient out of “Risk Zone”
44. Predicting risk Bisphosphonate-related ONJ :
CTX versus radiographic markers
Fleischer et al
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Vol. 110 No. 4 October 2010
48. Dental Logistics
• All Patients commencing Osteoporosis Treatment – should be “Dentally Fit”
• A “Certificate of Dental Fitness” prior to Osteoporotic Treatment is suggested
• Patients should not commence treatment until “Dentally Fit”
• Dental Treatment Planning should
– Reduce risk of oral surgical intervention for duration of treatment
– Dental Sepsis should be eradicated
– Periodontal Disease must be controlled
– Early extraction of teeth of poor prognosis
– Dental Implants not necessarily contraindicated
• IV Bisphosphonates
– Risk of ONJ
– More Aggressive Dental Assement / Treatment Planning
– Consider Dental Clearance
49. Certificate of Dental Fitness
Should be Mandatory
For any Patient being treated by any drugs that alter bone turnover
50. Certificate of Dental Fitness
Awareness
• General Medical Practitioners
• General Dental Practitioners
• Hospital Specialists
• Chief Medical Officers MOH
• Government - Department of Health
• Drug Companies
– Should advise that Certificate of Dental Fitness is mandatory prior to commencing treatment
– Inadequate Dental Care provision and action to prevent ONJ could be considered negligent
51. Certificate of Dental Fitness
Patient
Osteoporosis
Dental
Assessment
Dentally Fit?
Certificate of
Dental Fitness
Dental
Disease
Treatment
Dental Fit
Certificate of
Dental Fitness
Oral / IV Drug
Therapy
Malignancy
Dental
Assessemnt
Dentally Fit?
Certificate of
Dental Fitness
Dental
Disease
Treatment
Dentally Fit
Certificate of
Dental Fitness
IV Drug
Therapy
Avoid Future Extractions
Poor Prognosis of Dentition
Consider Dental Clearance
52. ONJ Prevention
Patient
Oral Drugs
Dental Assessment
Radiographs
Treatment Plan
CTX > 200pg/ML
Oral Surgery
CTX<200pg/ML
Repeat 3monthly
IV Drugs
Dental Assessment
Radiographs
Treatment Plan
CTX>200pg/mL
Oral Surgery
CTX < 200pg/ML
Repeat 3 Monthly
Drug Holiday
Drug Holiday: CTX 25 pg/mL / month
Consider Root Canal Therapy rather than Extractions in Irreversible / High Risk Cases
54. Antiresorbtive Medications
Intravenous (IV) bisphosphonates (BPs)
– hypercalcemia of malignancy
– skeletal-related events (SRE) breast, prostate and lung cancers
– multiple myeloma
– improvement of survival is controversial
– significant positive effect on the quality of life for patients
– IV BPs, ie once yearly infusion of zolendronate (Reclast®) and a parenteral formulation of ibandronate
(Boniva®) administered every three months, have FDA approval for management of osteoporosis
55. ONJ Incidence
• oncology patient population (1-15%)
• osteoporosis patient population, 0.001% - 0.01%
marginally higher than the incidence in the general population (<0.001%).
56. New Insights of ONJ Pathophysiology
• anti-resorptive effects of Bisphosphonates and Demosumab
• effects of BPs on gamma delta T-cells
• monocyte and macrophage function,
• as well as the role of local bacterial infection, inflammation and necrosis
57. Other ONJ Risk Factors
• glucocorticoid use
• maxillary or mandibular bone surgery
• poor oral hygiene
• chronic inflammation
• diabetes mellitus
• ill-fitting dentures
• other drugs, including anti-angiogenic agents.
58. Prevention Strategies for ONJ
• Elimination or stabilization of oral disease prior to initiation of anti-resorptive agents,
• As well as maintenance of good oral hygiene.
• In those patients at high risk for the development of ONJ
including cancer patients receiving high-dose BP or Dmab therapy
consideration should be given to withholding anti-resorptive therapy following extensive oral surgery
until the surgical site heals with mature mucosal coverage
59. Management of ONJ
• stage of the disease
• size of the lesions
• as well as the presence of contributing drug therapy and comorbidity
60. Management of ONJ
Conservative therapy
• antibiotic oral rinses
• systemic antibiotic therapy
Localized surgical debridement
• indicated in advanced non-responsive disease and has been successful.
• enhanced osseous wound healing with teriparatide risk of osteosarcoma?
• Experimental therapy includes
– bone marrow stem cell intralesional transplantation
– low-level laser therapy
– local platelet-derived growth factor application
– hyperbaric oxygen
– tissue grafting
61. Definition ONJ
Original Definition
“area of exposed bone in the maxillofacial region that does not heal
within eight weeks after identification by a health care provider,
in a patient who was receiving or had been exposed to a bisphosphonate
(BP) and has not received radiation therapy to the craniofacial region”
62. Definition ONJ Update AAOMS
Definition Update
1. current or previous treatment with anti-resorptive or anti-angiogenic agents
2. exposed bone or bone that can be probed through an intraoral or extraoral
fistula(e) in the maxillofacial region that has persisted for more than eight weeks
3. no history of radiation therapy to the jaws or obvious metastatic disease to the
jaws
63. Task Force Definition of ONJ
AAOMS Taskforce Definition
1. Exposed bone in the maxillofacial region that does not heal within
eight weeks after identification by a health care provider
2. Exposure to an anti-resorptive agent
3. No history of radiation therapy to the craniofacial region.
64. Oral Ulceration and Bone
Sequestration OUBS
OUBS
• oral ulceration and bone sequestration (OUBS) / absence of anti-resorptive therapy
• Uncommon but typically associated with significant morbidity
• OUBS described as “lingual mandibular sequestration and ulceration”
(predilection for involvement of posterior lingual mandibular bone)
• The sequestrum can slough spontaneously resulting in rapid resolution
• Some cases, conservative surgical removal of the dead bone is indicated to permit efficient
healing.
65. OUBS
• The incidence of OUBS in the general population is not well defined
• OUBS cases captured? in data pertaining to drug-related ONJ?
• Prevalence OUBS not known
66. OUBS - Differential Diagnosis
• alveolar osteitis
• Sinusitis
• gingivitis/periondontitis
• periapical pathosis
• cement-osseous dysplasia showing secondary sequestration.
Bone inflammation and infection are usually present in patients with
advanced ONJ, and appear to be secondary events.
Extremes of skeletal phenotypes [osteoporosis vs. osteopetrosis] (mice with altered expression of these molecules)
Research identified :
- the signaling mechanisms involved in the RANKL/RANK pathway
- metabolic bone disorders
common postmenopausal osteoporosis
rare (i.e. familial expansile osteolysis)
Control of osteoclastogenesis that has emerged in the post OPG/RANKL/RANK era.
RANKL on the surface of preosteoblastic/stromal cells binds to RANK on the osteoclastic precursor cells
M-CSF, binds to its receptor, c-Fms, on preosteoclastic cells, appears to be necessary for osteoclast development because it is the primary determinant of the pool of these precursor cells (32)
RANKL, however, is critical for the differentiation, fusion into multinucleated cells, activation, and survival of osteoclastic cells
OPG puts a brake on the entire system by blocking the effects of RANKL
A number of proresorptive cytokines, such as TNF- and IL-1, modulate this system primarily by stimulating M-CSF production (thereby increasing the pool of preosteoclastic cells) and by directly increasing RANKL expression (33)
In addition, a number of other cytokines and hormones, such as TGF-ß (increased OPG production) (34), PTH (increased RANKL/decreased OPG production) (35), 1,25-dihydroxyvitamin D3 (increased RANKL production) (36), glucocorticoids (increased RANKL/decreased OPG production) (37), and estrogen (increased OPG production) (38, 39) exert their effects on osteoclastogenesis by regulating osteoblastic/stromal cell production of OPG and RANKL
However, not all regulation of the osteoclast is exclusively via the osteoblast because calcitonin acts directly on osteoclastic cells (40), and estrogen has been shown to induce apoptosis of osteoclasts (41) as well as inhibit osteoclast differentiation by interfering with RANK signaling, principally RANKL-induced JNK activation and c-Jun activity and expression (42, 43)
Moreover, TGF-ß can also stimulate RANK expression on preosteoclastic cells, and thus enhance osteoclastic sensitivity to RANKL (44)
Recent studies have also found that the ability of preosteoblastic/stromal cells to support osteoclast development is lost rapidly during differentiation down the osteoblast pathway, due principally to down-regulation of RANKL and increased OPG production (45). Again, this makes eminent sense in terms of the basic multicellular unit, because whereas early osteoblastic cells in the marrow orchestrate the process of osteoclast development, it would clearly be counterproductive for the mature osteoblastic cells laying down osteoid on the bone surface to at the same time be stimulating osteoclast development, which would destroy the work they have just completed.
Control of osteoclastogenesis that has emerged in the post OPG/RANKL/RANK era.
RANKL on the surface of preosteoblastic/stromal cells binds to RANK on the osteoclastic precursor cells
M-CSF, binds to its receptor, c-Fms, on preosteoclastic cells, appears to be necessary for osteoclast development because it is the primary determinant of the pool of these precursor cells (32)
RANKL, however, is critical for the differentiation, fusion into multinucleated cells, activation, and survival of osteoclastic cells
OPG puts a brake on the entire system by blocking the effects of RANKL
A number of proresorptive cytokines, such as TNF- and IL-1, modulate this system primarily by stimulating M-CSF production (thereby increasing the pool of preosteoclastic cells) and by directly increasing RANKL expression (33)
In addition, a number of other cytokines and hormones, such as TGF-ß (increased OPG production) (34), PTH (increased RANKL/decreased OPG production) (35), 1,25-dihydroxyvitamin D3 (increased RANKL production) (36), glucocorticoids (increased RANKL/decreased OPG production) (37), and estrogen (increased OPG production) (38, 39) exert their effects on osteoclastogenesis by regulating osteoblastic/stromal cell production of OPG and RANKL
However, not all regulation of the osteoclast is exclusively via the osteoblast because calcitonin acts directly on osteoclastic cells (40), and estrogen has been shown to induce apoptosis of osteoclasts (41) as well as inhibit osteoclast differentiation by interfering with RANK signaling, principally RANKL-induced JNK activation and c-Jun activity and expression (42, 43)
Moreover, TGF-ß can also stimulate RANK expression on preosteoclastic cells, and thus enhance osteoclastic sensitivity to RANKL (44)
Recent studies have also found that the ability of preosteoblastic/stromal cells to support osteoclast development is lost rapidly during differentiation down the osteoblast pathway, due principally to down-regulation of RANKL and increased OPG production (45). Again, this makes eminent sense in terms of the basic multicellular unit, because whereas early osteoblastic cells in the marrow orchestrate the process of osteoclast development, it would clearly be counterproductive for the mature osteoblastic cells laying down osteoid on the bone surface to at the same time be stimulating osteoclast development, which would destroy the work they have just completed.
Reports of osteonecrosis (also called "osteochemonecrosis" and "bisphosphonate-associated osteonecrosis") of the jaw associated with the use of the bisphosphonates zoledronic acid (Zometa, Novartis, East Hanover, N.J.) and pamidronate (Aredia, Novartis), began to surface in 2003.1,2 Zoledronic acid and pamidronate are intravenous (IV) bisphosphonates used to reduce bone pain, hypercalcemia of malignancy and skeletal complications in patients with multiple myeloma, breast, lung and other cancers and Paget’s disease of bone. The majority of reported cases of bisphosphonate-associated osteonecrosis (BON) of the jaw have been diagnosed after dental procedures such as tooth extraction. Less commonly, BON appears to occur spontaneously in patients taking these drugs.3
As of early 2006, cases of BON also had been reported in individuals taking orally administered nitrogen-containing bisphosphonates, used for the treatment of osteoporosis.3–5 The total number of reported cases of possible BON in people taking alendronate (Fosamax, Merck & Co., Whitehouse Station, N.J.) is approximately 170 worldwide, according to Merck & Co. (C. Arsever, oral communication, March 2006); approximately 12 in people taking risedronate (Actonel), according to Procter & Gamble Pharmaceuticals, Cincinnati (M. Schorr, oral communication, March 2006); and approximately one in a person taking ibandronate (Boniva, Roche Pharmaceuticals, Basel, Switzerland), according to Roche (J. Travis, oral communication, March 2006). For alendronate (the most commonly prescribed oral bisphosphonate), this translates into a spontaneous BON incidence (or rate at which new cases occur) of approximately 0.7 cases per one hundred thousand person-years’ exposure. To date, a true cause-and-effect relationship between osteonecrosis of the jaw and bisphosphonate use has not been established. Table 1 lists all oral and IV bisphosphonates on the market in the United States.
The morning fasting serum CTX test is one of several known serum and urine tests that measures a breakdown product of bone resorption.
The CTX specifically measures a specific crosslink peptide of type I collagen in bone (98% of the total protein in bone).
The serum CTX is considered to best correlate to bone turnover and was chosen due to the fact that a single laboratory (Quest Diagnostics Nichols East Lab in San Juan Capistrano, California) performs this test under standard conditions.
The telopeptide fragment in question is cleaved from the main crosslink chains of collagen by the osteoclast during bone resorption. Its level in the serum is therefore proportional to the amount of osteoclastic resorption occurring at the time the blood is drawn. Even though laboratory normal ranges are said to be between 50 pg/mL and 450
pg/mL, this normal range is not accurate related to the osteoporosis population. Actual normal values are usually well over 300 pg/mL and are most commonly 400 pg/mL to 550 pg/mL in patients not taking bisphosphonates. Lower values represent varying degrees of suppression of normal bone turnover sometimes also called bone remodeling or bone renewal.
Current opinion is that oral surgery can be carried out at a level of 100pg/100mls* but that treatment is safer with
CTX BETA CROSSLAPS >200pg/100mls**
*Therapeutic Guidelines. Therapeutic guidelines: oral and dental. Melbourne: TG, 2007.
**Ref: Goss AN. CTX (the cross laps test). Australian Dental Association Bulletin 2008; 368:11.